Compositions and methods for modulating apolipoprotein C-III expression
Provided herein are oligomeric compounds with conjugate groups targeting apolipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
1. A compound comprising a single stranded modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 12 to 30 linked nucleosides and has a nucleobase sequence comprising a portion of at least 8 contiguous nucleobases fully complementary to an equal length portion of nucleobases 3533 to 3552 of SEQ ID NO: 3, wherein the nucleobase sequence of the modified oligonucleotide is at least 80% complementary to SEQ ID NO: 3 over the entire length; and wherein the conjugate group is linked to the modified oligonucleotide at the 5′ end of the modified oligonucleotide by a conjugate linker; wherein the conjugate group comprises:
wherein each n is, independently, from 1 to 20; and
wherein the conjugate linker has a structure selected from among:
wherein each L is, independently, a phosphorus linking group or a neutral linking group;
and each n is, independently, from 1 to 20; or
wherein each n is, independently, is from 1 to 20; and p is from 1 to 6; or
wherein each n is, independently, from 1 to 20; or
2. The compound of claim 1 , wherein the nucleobase sequence of the modified oligonucleotide is at least 85%, at least 90%, at least 95%, or 100% complementary to SEQ ID NOs: 3.
3. The compound of claim 1 , wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.
4. The compound of claim 3 , wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.
5. The compound of claim 1 , wherein the modified oligonucleotide comprises at least one modified sugar.
6. The compound of claim 5 , wherein at least one modified sugar is selected from a bicyclic sugar, a 2′-O-methoxyethyl modified sugar, a constrained ethyl modified sugar, a 3′-fluoro-HNA or a 4′-(CH 2 ) n —O-2′ bridge, wherein n is 1 or 2.
7. The compound of claim 1 , wherein at least one nucleoside comprises a modified nucleobase.
8. The compound of claim 7 , wherein the modified nucleobase is a 5-methylcytosine.
9. The compound of claim 1 , wherein the modified oligonucleotide comprises:
a gap segment consisting of linked deoxynucleosides;
a 5′ wing segment consisting of linked nucleosides;
a 3′ wing segment consisting of linked nucleosides;
wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.
10. The compound claim 1 , wherein the modified oligonucleotide comprises:
a gap segment consisting of ten linked deoxynucleosides;
a 5′ wing segment consisting of five linked nucleosides;
a 3′ wing segment consisting of five linked nucleosides;
wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment, wherein each nucleoside of each wing segment comprises a 2′-O-methoxyethyl sugar, and wherein each cytosine residue is a 5-methylcytosine.
11. The compound of claim 1 , wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage.
12. The compound of claim 10 , wherein the modified oligonucleotide consists of 20 linked nucleosides.
13. The compound of claim 1 , wherein the conjugate linker has a structure selected from among:
wherein each L is, independently, a phosphorus linking group or a neutral linking group; and
each n is, independently, from 1 to 20.
14. The compound of claim 1 , wherein the conjugate linker has a structure selected from among:
15. The compound of claim 1 , wherein the conjugate linker has the following structure:
16. The compound of claim 1 , wherein the conjugate linker has the following structure:
17. The compound of claim 1 , wherein the conjugate linker has a structure selected from among:
18. The compound of claim 1 , wherein the conjugate linker has a structure selected from among:
19. The compound of claim 1 , wherein the conjugate linker has a structure selected from among:
20. The compound of claim 1 , wherein the conjugate linker has a structure selected from among:
wherein each n is, independently, is from 1 to 20; and p is from 1 to 6.
21. The compound of claim 1 , wherein the conjugate linker has a structure selected from among:
wherein each n is, independently, from 1 to 20.
22. The compound of claim 1 , wherein the conjugate linker has a structure selected from among:
23. The compound of claim 1 , wherein the conjugate linker has a structure selected from among:
24. The compound of claim 1 , wherein the conjugate linker has a structure selected from among:
wherein each n is independently, 0, 1, 2, 3, 4, 5, 6, or 7.
25. The compound of claim 1 , wherein the conjugate linker has the following structure:
26. The compound of claim 1 , wherein the conjugate group comprises:
and the conjugate linker has the following structure:
27. The compound of claim 1 , wherein the conjugate group comprises a cleavable moiety selected from a phosphodiester, an amide, and an ester.
28. The compound of claim 1 , wherein the conjugate comprises:
29. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
30. A method comprising administering to an animal the composition of claim 29 .
31. The method of claim 30 wherein the animal is a human.
32. The method of claim 30 , for use in treating, preventing, or slowing progression of a disease related to elevated ApoCIII.
33. The method of claim 30 , wherein administering the compound prevents, treats, ameliorates, or slows progression of a cardiovascular, metabolic and/or inflammatory disease, disorder or condition in the animal.
34. The method of claim 30 , wherein the animal has, or is at risk of having, any one or more of hypertriglyceridemia, Fredrickson Type I dyslipidemia, FCS, LPLD, pancreatitis, diabetes, and insulin insensitivity.